Extramedullary disease in multiple myeloma.

Introduction

Multiple Myeloma (MM) is defined by the presence of ≥10% clonal bone marrow (BM) plasma cells (PC) associated with features of hypercalcemia, renal failure, anemia or lytic bone lesions or the presence of biomarkers such as ≥60% BMPC, involved to uninvolved FLC ratio ≥100, or the presence of ≥2 marrow lesions on MRI [ 1 ]. Despite high-dose chemotherapy with stem cell support (HDT) and novel therapeutic agents, prognosis remains poor. When a sub-clone of PCs is able to grow outside of marrow, it results in development of disease outside the marrow, termed as extramedullary multiple myeloma (EMD).

Classification

The term extramedullary can be confusing and as there is a lack of consensus regarding the classification, we put forward a convenient way to classify them in a manner that reflects the prognosis and the therapeutic approach (Table 1 ) [ 1 – 6 ]. EMD can be present either at initial diagnosis (primary EMD) or at relapse (secondary EMD) [ 3 , 7 ]. Table 1 Classification of EMD. Type of EMD Definition a. Solitary Plasmacytoma (SP) with no marrow involvement Biopsy-proven bone or soft tissue lesion with evidence of clonal plasma cells. However, marrow has no clonal PCs and no additional abnormality on imaging and absence of CRAB criteria. b. Solitary plasmacytoma with minimal marrow involvement SP with <10% clonal BMPC c. Bone associated EMD with MM (EMM) Soft tissue mass arising from bone lesions and growing contiguously d. Bone independent EMD with MM (EMM) Isolated extra-osseous plasma cell tumors not contiguous with bone lesions e. Organ infiltrating EMD CNS myeloma, diffuse liver involvement etc f. Plasma cell leukemia (PCL) Traditionally, this aggressive variant of MM was defined by the presence of circulating PCs (>20% and/or absolute count >2 × 10 9 /L). However, this criteria was updated recently by including those with ≥5% cPCs or an absolute number ≥0.5 × 10 9 cells/L detected morphologically on a peripheral blood smear [ 5 ]. The corresponding quantitative cutoff for circulating PCs was determined as 200 cPCs/µl on multiparametric flow cytometry [ 8 ].

The symptoms due to EMD are typically related to the site of lesions—a summary of literature regarding sites involved in EMD is provided in Table 2 . Table 2 Summary of sites involved in EMD with presentation and treatment options. Site involved Presentation Incidence OS Treatment options Ref CNS- Brain parenchyma or meninges Lethargy, nausea or vomiting, headache, confusion, paresthesia or seizures; visual, gait, and speech disturbances 3% 1 month Whole brain radiation therapy, intrathecal chemotherapy, and systemic chemotherapy [ 46 ] Skull Smooth, firm, and non-tender mass on skull <1% High-dose dexamethasone [ 3 ] Orbit Generally unilateral soft tissue orbital mass with complaints of headache, proptosis which is painless in nature, decreased vision, diplopia, restriction of eye movement and swelling, corneal crystalline deposits <1% 28 months Local excision as a salvage surgery, whole brain radiation therapy, intrathecal chemotherapy, and systemic chemotherapy [ 47 ] Vertebrae Spinal cord or root compression, back pain <1% – RT, intrathecal chemotherapy [ 48 ] Breast Breast lump ranging from 1 to 7.5 cms 9% in primary EMD and 3% in secondary EMD – Surgical excision with adjuvant RT. Chemotherapy should be considered for tumors greater than 5 cm, high grade tumors and patients with refractory and / or relapsed disease. SCT. [ 11 , 35 , 49 ] Thyroid Painful swelling on the side of the neck accompanied with odynophagia, dysphagia, and hoarseness 2.9% – Chemotherapy with or without autologous SCT. External beam RT –when organ function loss is contemplated post-surgery. [ 50 – 52 ] Soft tissue of neck Soft tissue swelling in the neck, unilateral nasal obstruction, more common in males, associated with epistaxis, facial swelling, pain and rhinorrhea. Can also present with headache, ptosis, diplopia, CN palsies II, III, IV, VI is sphenoid sinus is involved 10% – Tumor size <5 cm-RT 30-40 Gy #20 Tumor size >5 cms- RT 40-50 Gy. Chemotherapy is considered if tumor size >5 cm, high-grade tumor, refractory/relapsed disease. Surgical excision may be considered. [ 25 , 26 , 53 , 54 ] Lungs Unilateral Pleural effusion (right>left), pulmonary nodule, hilar mass, with atypical symptoms. Can have concurrent ascites 2.65% 2.8–4 months Intrapleural bortezomib biweekly during induction and weekly or fortnightly during consolidation and maintenance along with systemic chemotherapy, concurrent pleurodesis or ICD drainage [ 55 ] Spleen Silent course, incidental finding on autopsies, can rarely present with left upper quadrant pain, painful splenomegaly, rarely splenic rupture 9% in primary EMD and 11.5% IN secondary EMD – Splenectomy [ 11 , 56 ] Heart Male preponderance, presents with dyspnea, tachycardia, pericardial effusion with or without tamponade, distant heart sounds, distended neck veins and positive kussmaul sign, pericardial or atrial mass 0.4% 13.5 weeks Pericardial window for drainage, chemotherapy +/− high dose cortocosteroids [ 57 ] Liver Hepatomegaly, jaundice, ascites, and fulminant liver failure, mildly elevated liver transaminase levels 28.8% – Systemic chemotherapy [ 56 ] Pancreas Decreased appetite, worsening peri-umbilical discomfort, pulsatile abdominal mass, bilateral rib pain, jaundice, homogeneous solid mass on CT 2.3% 7 months Systemic chemotherapy such as with VRD, RT, SCTation [ 58 ] Gatro-intestinal tract Non-specific gastrointestinal symptoms, including anorexia and weight loss, abdominal pain, vomiting, and, rarely, gastrointestinal bleeding, usually from an ulcerated lesion. small bowel is the most common site of involvement, followed by stomach, colon, and esophagus. <5% – RT or surgery along with systemic chemotherapy [ 59 ] Omentum Ascites, generally an autopsy finding – 1.5 months – [ 60 ] Testis Testicular swelling, erythema, pain may or may not be present 0.1% Radical orchiectomy [ 61 ] Skin Centrifugal appearance of multiple erythematous nodules or papules, or plaques that show a nodular or diffuse interstitial pattern. 1.14% 0.4–108 months (8.5 months) Chemotherapy, RT, SCT [ 62 ] Subcutaneous tissue Single or multiple large highly vascularized subcutaneous nodules with a red-purple appearance 0.6% – bortezomib-containing regimen followed by ASCT Lymph node Non-tender, enlarged lymph nodes. Weight loss maybe present. Most common site- paratracheal lymph node 23.1% – – [ 56 ] Muscle Symmetric proximal muscle weakness and tenderness 4.5% – Systemic chemotherapy [ 11 ] Female reproductive system Pelvic pain, profuse menorrhagia, and severe anemia – – total abdominal hysterectomy with bilateral salpingo-oophorectomy Adrenal glands Incidental finding on imaging or autopsies 7.7% – Surgical excision [ 56 ] - insufficient data.

Epidemiology

Overall incidence of EMM is 13%:7% at diagnosis and 6–20% at relapse [ 8 ]. 85% of these are bone-associated and the median age for patients is higher as compared to patients with bone-independent EMD (71 vs 60.5 years) [ 2 ]. There has been an overall increase in the incidence of EMM from 6.5% in 2005 to 23.7% in 2014 [ 9 ]. Median time from diagnosis to occurrence of EMM has been observed to be 19–23 months [ 2 , 8 ]. The results of total therapy protocol trials also reported that extra medullary involvement at presentation was more common among those with high-risk translocations t(14;16) and t(14;20) and was associated with poor overall survival (OS) [ 10 ].

Patients with osteolytic lesions and hypercalcemia are at a higher risk for developing EMD. Other significant risk factors include therapeutic history (>2 lines of treatment ± treatment duration >6 months) and allogenic SCT (auto-allo-SCT) [ 11 , 12 ]. It is quite possible that the increasing frequency of EMD at relapse among patients with MM reflects the improved OS in general and that we are seeing a phase of the disease we did not reach before the advent of newer therapies.

Pathogenesis

The interaction between myeloma cells and the BM microenvironment activates signaling cascades and mediates chemotaxis and adhesion of myeloma cells to BM (Fig. 1 ). The adhesion is augmented by binding of stromal-derived factor 1 a (SDF 1-A) to CXCR4 receptor and adhesion molecules like VLA-4, P-selectin, CD 56, and CD 44 [ 13 ]. Tumor dissemination occurs due to (i) low expression of chemokine receptors and adhesion molecules [ 4 ], (ii) underexpression of membrane-embedded CS81/CD 82 tetraspanins [ 14 ] and overexpression of tumor promoter heparanase enzyme, (iii) upregulation of CXCR4 by various growth factors and hypoxic conditions in tumor microenvironment [ 15 ] and acquisition of EM phenotype regulated by CXCR4 [ 15 , 16 ]. A possible PCAT-1/Wnt β-catenin signaling axis has also been implicated in growth, OS, and migration of MM cells [ 17 , 18 ]. Head and neck and liver have been reported as the most common location at diagnosis followed by pleural fluid at relapse [ 19 ]. It was hypothesized that specific tropism or homing of EMM clones makes them more prone to trafficking to these sites. Fig. 1 Pathogenesis of extramedullary spread in multiple myeloma. SDF-1- Stromal cell derived factor-1, CXCR-4- Chemokine receptor type 4, VLA-4- Very late antigen-4, VCAM-1- Vascular cell adhesion protein-1, VEGF- Vascular endothelial growth factor, TNF-a- Tumor necrosis factor- alpha, HGF- Hepatocyte growth factor, IL-6- Interleukin-6.

Recent studies have revealed that long non-coding RNA like MALAT1 and MEG-3 regulate gene expression at the transcriptional, post‐transcriptional, and epigenetic levels and are involved in tumor initiation, metastasis, and drug resistance [ 20 ]. MALAT1 located on chromosome 11 was observed to be markedly higher in EMD as compared to intramedullary MM cells [ 21 ]. It was observed that patients with a greater decrease in MALAT1 after initial treatment had a significantly prolonged progression‐free survival (PFS) duration, while patients with smaller MALAT1 changes after treatment had a significantly higher risk of early progression [ 21 ].

Immunophenotype

Studies have shown that EMDs have a higher proliferative index, lower p27 expression, and CCND-1 and p53 co-positivity [ 22 ]. BCl-2 and Bcl-xl are strongly positive, CD56 is downregulated and CD44 is upregulated [ 22 , 23 ]. Immuno-phenotyping helps not only in identifying the cell but also in establishing the correct diagnosis.

Cytogenetic profile

Genetic aberrations in myeloma are usually identified using Fluorescence in-situ hybridization (FISH) and have an important prognostic value in MM. However, cytogenetic features of EMD are not well defined in literature. A few studies have reported association of high-risk cytogenetics like t(4;14), t(14;16), gain(1q21), and del(17p) in patients with EMD [ 2 , 24 , 25 ]. Studies have also identified del(17p13) and del(13q14) as markers for progression to EMD [ 2 , 26 ] and del(13) as risk factor for EM relapse. Gain(1q) was associated with inferior outcome [ 27 ]. High risk cytogenetics was more frequent in patients with organ involvement (47%) vs EMM [ 28 ].

Clinical evaluation

Along with the routine myeloma workup, EMD requires a tumor biopsy/FNAC for immune-histochemistry (Table 3 ) and a BM biopsy to evaluate PC morphology and the degree of total PC infiltration [ 29 ]. Patients who develop EM spread during their disease course have significantly lower levels of serum M-protein and hemoglobin and significantly higher levels of lactate dehydrogenase (LDH) than those who present with EMD at diagnosis [ 8 ]. Using sensitive imaging techniques including MRI and PET/CT, EMD may be found in up to 30% of MM patients across the overall disease course. Table 3 Recommended workup for EM multiple myeloma. Diagnostic tools Comments Laboratory Complete blood count with differential, peripheral smear Chemistry—Creatinine, albumin, corrected calcium Lactate dehydrogenase Beta-2 microglobulin Serum quantitative immunoglobulins Serum protein electrophoresis Serum Free Light Chain (FLC) assay Urine—24-h urine for total protein, urine protein electrophoresis Bone marrow aspiration and biopsy If no plasma cells are detected—SP with no marrow involvement If <10% plasma cells are detected—SP with minimal marrow involvement FISH if plasma cells identified Tumor biopsy/sampling Usually sheets of plasma cells, identifiable by morphology IHC if required for light chain restriction Ki67 stains can help determine proliferation rate FISH, mutation panel (if applicable) Radiology Skeletal survey 18 Fluorodeoxyglucose positron emission tomography (FDG-PET) Computed tomography (CT), Magnetic resonance imaging (MRI) Multiparameter flow cytometry True solitary plasmacytoma—characterized by flow-negative bone marrow and absence of M protein Circulating plasma cells >200 cPCs/µL - PCL

Treatment

EMM

Radiotherapy (RT)

There is no consensus on use of RT in EMM except for SP. A few cases have reported the use of RT with good outcomes in EMD as outlined in Table 2 .

Induction chemotherapy

With a rising incidence of EMD in the era of novel agents, it was hypothesized that newer drugs lead to drug resistant, inherently aggressive, and BM-independent clones [ 7 ]. However, there is no clinical evidence supporting the same [ 30 ]. Superior complete response rates in de-novo EMD patients have been reported with novel agents (thalidomide, lenalidomide and bortezomib-based regimens) vs conventional chemotherapy [ 31 ] (Table 4 ). In relapsed/refractory (r/R) patients with EMD, lymphoma-like polychemotherapy regimen such as PACE (cisplatin, doxorubicin, cyclophosphamide, and Etoposide), Dexa-BEAM, and HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) followed by ASCT (ASCT) or auto-allo-SCT have been successful [ 32 , 33 ]. Newer generation IMiDs such as pomalidomide have also been effective at the time of relapse [ 7 ]. Carfilzomib is also active but has inferior outcomes in bone-independent EMD compared to bone-related EMD [ 34 ]. One should consider the previous lines of therapy and the duration of response at relapse. Table 4 Summary of studies evaluating treatment options for EMD. Author Patient group Treatment arm (% of patients) Type of EMD Complete response rate (%) Median PFS (months) Median OS (months) Limitation of study Ref Gagelmann et al. [ 28 ] Newly diagnosed MM with EMD (488)—40% with high risk cytogenetics Bortezomib-based induction (73) 21 4 year PFS-42% 4 year OS-69% Absence of data on maintenance therapy, salvage treatment, or details on induction therapy beyond whether bortezomib was used or not [ 37 ] Non-bortezomib-based induction (27) 17 4 year PFS-34% 4 year OS-64% First line ASCT (77) 4 year PFS-43% 4 year OS-70% Tandem ASCT (17) 4 year PFS-52% 4 year OS-83% Auto–allogeniec transplant (6) 4 year PFS-58% 4 year OS-88% Beksac et al. [ 46 ] Newly diagnosed EMD (130/226) Initial therapy—IMiD-based (74.7%)/ PI-based (10%) followed by ASCT (51.5%) Bone-independent MM 19.3 38.9 46.5 Selection bias—age < 45 not included [ 56 ] Bone-associated MM 34.2 51.7 N.R. EMD at relapse (96/226) Initial therapy—IMiD-based (10.4)/ PI- based(41.7%) followed by ASCT (4.1%) Bone-independent MM 9 13.6 11.4 Bone-associated MM 54.5 20.9 39.8 Gagelmann et al. [ 9 ] Adult patients with EMD at diagnosis who received single ASCT within 12 months of diagnosis or a tandem ASCT within six months from first ASCT as first line therapy (682/3744) Pre-ASCT Bone-independent MM 11.7 N.R. (3 year PFS-59.8%) N.R. (3 year OS-83.6%) Selection bias—elderly patients not transplanted are not included [ 10 ] Bone-associated MM 21.5 Post-ASCT Bone-independent MM 36.1 24 N.R. (3 year OS-58%) Bone-associated MM 41.6 36 N.R. (3 year OS-77.7%) Post-tandem ASCT Bone-independent MM N.R. (3 year PFS-56.2%) N.R. (3 year OS-52%) Bone-associated MM N.R. (3 year PFS-59.4%) N.R. (3 year OS-82.6%) Kumar L et al. [ 31 ] EMD at diagnosis or prior to ASCT (44/271) with 200 mg/m 2 melphan conditioning Initial therapy- Novel agents (52.3%) EMD 52.2% (12/23) 18 32 Small sample size. Lack of cytogenetic data. [ 42 ] VDD and alkylating agents (47.7%) 9% (2/21) Shin et al. [ 24 ] EMD at diagnosis or prior to ASCT with 88.2% patients receiving 200 mg/m 2 melphan conditioning (93/239) Initial Therapy- TCD (34.5%)/ VAD (27.6%)/ RT (51.7%) Bone-independent MM 31 12 37 [ 33 ] Initial Therapy- TCD (29.7%)/ VAD (37.5%)/ RT (45.3%) Bone- associated MM 40.6 28 67 Gozzetti et al. [ 35 ] Intra cranial-MM (50) Autologous/ allogenic SCT- (24%) CNS EMD and osteodural EMD 50% 34 46 [ 63 ] Chemotherapy- novel and old agents (72%) 5 12 RT (32%) 12 25 Short et al. [ 7 ] EMD in relapsed refractory MM (13/174) Patients had prior exposure to bortezomib (78%), IMiD agents -thalidomide or lenalidomide (100%) before the diagnosis of EMD Pomalidomide plus low-dose dexamethasone in phase II clinical trial Primary bone-independent MM 15.4 16 Only included bone-independent MM. Bone-associated MM were excluded [ 7 ] Treatment-emergent Bone-independent MM PFS Progression free survival, OS Overall Survival, N.R. Not Reached, TCD [thalidomide, cyclophosphamide, and dexamethasone, VAD [vincristine, adriamycin, and dexamethasone, VDD [vincristine, doxorubicin, and dexamethasone, ASCT Autologous stem-cell transplant.

Extramedullary tumor masses in CNS most frequently arise from bone lesions in the cranial vault, skull base, nose, or paranasal sinuses, whereas primary dural (pachy-meningeal) involvement is rare. The OS with osteodural involvement (25 months) is three times more than leptomeningeal involvement (6 months) [ 35 ]. For CNS EMD, a combination of CNS directed treatment including RT and IT chemotherapy and systemic therapy including novel agents which can cross blood brain barrier (BBB) has shown activity [ 35 , 36 ]. IMIDs are more likely to cross BBB than PIs and more prospective data is needed to determine ideal strategy [ 37 ].

There is paucity of data with use of Daratumumab in EMD. An updated pooled analysis of studies (GEN501 part 2 and SIRIUS) evaluating role of daratumumab in heavily pre-treated patients reported an overall response rate (ORR) in subset of patients with EM involvement was 16.7% (95% CI: 3.6–41.4) with improved OS in responders/minimal response/stable disease [ 38 ]. There are also several case reports with response to daratumumab in EMD.

Innovative approaches using adoptive cell therapies (chimeric antigen receptor T cells) have recently shown promising results in a limited number of relapsed patients with EMD [ 39 ]. In a meta-analysis on BCMA CAR-T cell therapy, the presence of EM disease at time of infusion was not associated with lower response rates showing a pooled response rate of 78% vs 82% overall [ 40 ]. The high response rates with anti-BCMA CAR-T therapy despite EM disease demonstrate the need for more focused subgroup analysis in upcoming CAR-T studies.

SCT

The preferred next step in patients who respond to induction therapy is transplant. However, the benefit of ASCT in patients with EMD appears to be more limited. The Spanish PETHEMA group observed a significantly shorter median OS (46.7 months vs NR) but no significant difference in 2-year PFS after ASCT with high-dose melphalan conditioning. The poor outcome after single ASCT can be attributed to high-risk cytogenetics which can be found in almost 40% patients with EMM. Single vs multiple sites of EMD as well as organ involved can also impact prognosis after ASCT [ 9 ]. Upfront tandem transplant has been shown to overcome poor outcomes in these patients compared to single ASCT [ 28 ]. Studies evaluating tandem transplantation suggest high-risk subgroups, including patients failing to achieve VGPR after single ASCT, International Staging System (ISS) stage II/III, and high-risk cytogenetics, may benefit most from tandem transplantation [ 41 ]. However, a EBMT registry study reported similar 3-year PFS and OS with both first-line tandem and single ASCT in patients with EMD [ 9 , 42 ]. (Table 4 ).

Relapse after transplant

Patients with MM with EMD at diagnosis or during the disease course have a higher risk of EMD at relapse following HDT. The relapse rate is generally similar between bone-independent MM and bone-associated MM [ 24 ]. Various sites like bone, abdomen, and chest have been reported to be involved at the time of relapse [ 19 , 24 ]. Although the mechanism is largely unclear, but worsening disease status at time of transplant may enhance the risk of EMM [ 43 ].

Gagelman et al. reported cumulative incidence of relapse in NDMM patients with EMD as 54% after single ASCT, 47% after tandem ASCT, and 30% after auto–allogeneic transplant [ 28 ]. Even though allo-SCT is associated with long-term disease-free OS, it is associated with high transplant-related mortality. A higher incidence of EM relapse (45–55%) has been observed with auto-allo-SCT with reduced intensity conditioning (RIC) [ 44 ]. A German study used auto-allo-SCT either as first line treatment or at the time of relapse as the escalation approach. They reported relapse in 49% of the patients with EMD present in one-third of the cohort. OS in EMD group was significantly inferior as compared to intramedullary relapse [ 45 ]. Allo-SCT takes advantage of a tumor cell-free graft along with the graft-versus-myeloma (GVM) effect targeting residual malignant plasma cells. Furthermore, allo-SCT allows for donor lymphocyte infusions as an additional intervention that has shown remarkable responses, clearly demonstrating the intensification of a GVM effect. Hence, in patients requiring rescue therapy, allo-RIC should be considered as a platform for additional therapeutic strategies after transplantation to take advantage of the GVM effect.

Prognosis

EM involvement is one of the indicators of poor prognosis in MM, with high mortality and an average OS time of 36 months [ 10 , 35 ]. Factors causing worse progression-free OS and OS: (a) EMD, (b) EMD at relapse, (c) bone-independent EMD with MM, (d) multiple organ involvement, (e) CNS involvement, (f) No ASCT, (g) not achieved complete response post-SCT, (h) β2-microglobulin >5 mmol/L, (i) ISS II & III (j) acute GVHD [ 9 , 31 , 35 , 44 , 46 ]. On multivariate analysis, Shin et al. also reported platelet counts as predictive of poor PFS and bone marrow plasma cell percentage as predictive for poor OS after ASCT [ 24 ].

Cause of death

The EBMT report on EM multiple myeloma observed non-relapse mortality (NRM) at three years in 3% patients with bone associated EMD, and 7% in patients with EM organ involvement. The main causes of death were relapse or progression (86.3%), infection (7.1%), secondary malignancy or post-SCT lymphoproliferative disorder (3.6%), organ damage or failure (1.8%) and toxicity (0.4%) [ 9 ].

Future considerations

EMD presents a spectrum of disease presentations in MM with ill-defined boundaries. There is an urgent need for consensus on criteria defining EMD. The incidence of EMD is largely underestimated due to lack of prospective studies on large cohorts. New guidelines should be formulated which provide algorithms for treatment and follow-up of EMD using RT, chemotherapy, and surgery considering category, location, and tumor size. Large, randomized multi-center studies with long follow up are required to assess the efficacy and safety of available treatment options. Newer drugs like monoclonal antibodies, immunotherapy, and BCL-2 inhibitors are also worth exploring.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Competing interests

The authors declare no competing interests.

References

1. Rajkumar SV Dimopoulos MA Palumbo A Blade J Merlini G Mateos MV International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 2014 15 e538 48 10.1016/S1470-2045(14)70442-5 25439696

2. Billecke L Murga Penas EM May AM Engelhardt M Nagler A Leiba M Cytogenetics of extramedullary manifestations in multiple myeloma Br J Haematol 2013 161 87 94 10.1111/bjh.12223 23368088

3. Pour L Sevcikova S Greslikova H Kupska R Majkova P Zahradova L Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse Haematologica 2014 99 360 4 10.3324/haematol.2013.094409 24038024 PMC3912968

4. Bladé J Fernández de Larrea C Rosiñol L Cibeira MT Jiménez R Powles R Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach J Clin Oncol 2011 29 3805 12 10.1200/JCO.2011.34.9290 21900099

5. Fernández de Larrea C Kyle RA Durie BGM Ludwig H Usmani S Vesole DH Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group Leukemia 2013 27 780 91 10.1038/leu.2012.336 23288300 PMC4112539

6. Deng S Xu Y An G Sui W Zou D Zhao Y Features of extramedullary disease of multiple myeloma: high frequency of p53 deletion and poor survival: a retrospective single-center study of 834 cases Clin Lymphoma Myeloma Leuk 2015 15 286 91 10.1016/j.clml.2014.12.013 25640025

7. Short KD Rajkumar SV Larson D Buadi F Hayman S Dispenzieri A Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma Leukemia 2011 25 906 8 10.1038/leu.2011.29 21350560 PMC3736849

8. Varettoni M Corso A Pica G Mangiacavalli S Pascutto C Lazzarino M Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients Ann Oncol 2009 21 325 30 10.1093/annonc/mdp329 19633044

9. Gagelmann N Eikema DJ Iacobelli S Koster L Nahi H Stoppa AM Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT Haematologica 2018 103 890 7 10.3324/haematol.2017.178434 29419433 PMC5927971

10. Usmani SZ Heuck C Mitchell A Szymonifka J Nair B Hoering A Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents Haematologica 2012 97 1761 7 10.3324/haematol.2012.065698 22689675 PMC3487453

11. Mangiacavalli S Pompa A Ferretti V Klersy C Cocito F Varettoni M The possible role of burden of therapy on the risk of myeloma extramedullary spread Ann Hematol 2017 96 73 80 10.1007/s00277-016-2847-z 27766391

12. Chong G Byrnes G Szer J Grigg A Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy Bone Marrow Transplant 2000 26 1011 5 10.1038/sj.bmt.1702659 11100282

13. Alsayed Y Ngo H Runnels J Leleu X Singha UK Pitsillides CM Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma Blood 2007 109 2708 17 10.1182/blood-2006-07-035857 17119115 PMC1852222

14. Tohami T Drucker L Shapiro H Radnay J Lishner M Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential FASEB J 2007 21 691 9 10.1096/fj.06-6610com 17210782

15. Azab AK Hu J Quang P Azab F Pitsillides C Awwad R Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features Blood 2012 119 5782 94 10.1182/blood-2011-09-380410 22394600 PMC3382938

16. Jung O Trapp-Stamborski V Purushothaman A Jin H Wang H Sanderson RD Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins Oncogenesis 2016 5 e202. 10.1038/oncsis.2016.5 26926788 PMC5154350

17. Qiang YW Chen Y Brown N Hu B Epstein J Barlogie B Characterization of Wnt/β‐catenin signalling in osteoclasts in multiple myeloma Br J Haematol 2010 148 726 38 10.1111/j.1365-2141.2009.08009.x 19961481 PMC3683858

18. Shen X Zhang Y Wu X Guo Y Shi W Qi J Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum Cancer Biomark 2017 18 257 63 10.3233/CBM-160158 28085010 PMC13020597

19. Weinstock M Aljawai Y Morgan EA Laubach J Gannon M Roccaro AM Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation Br J Haematol 2015 169 851 8 10.1111/bjh.13383 25833301 PMC5944324

20. Zhuang W Ge X Yang S Huang M Zhuang W Chen P Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription Stem Cells 2015 33 1985 97 10.1002/stem.1989 25753650

21. Handa H Kuroda Y Kimura K Masuda Y Hattori H Alkebsi L Long non‐coding RNA MALAT 1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma Br J Haematol 2017 179 449 60 10.1111/bjh.14882 28770558

22. Kremer M Ott G Nathrath M Specht K Stecker K Alexiou C Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis J Pathol 2005 205 92 101 10.1002/path.1680 15586381

23. Dahl IM Rasmussen T Kauric G Husebekk A Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma Br J Haematol 2002 116 273 7 10.1046/j.1365-2141.2002.03258.x 11841427

24. Shin HJ Kim K Lee JW Song MK Lee JJ Lee HS Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma Eur J Haematol 2014 93 414 21 10.1111/ejh.12377 24813053

25. Besse L Sedlarikova L Greslikova H Kupska R Almasi M Penka M Cytogenetics in multiple myeloma patients progressing into extramedullary disease Eur J Haematol 2016 97 93 100 10.1111/ejh.12688 26432667

26. Avivi I Cohen YC Suska A Shragai T Mikala G Garderet L Hematogenous extramedullary relapse in multiple myeloma—a multicenter retrospective study in 127 patients Am J Hematol 2019 94 1132 40 10.1002/ajh.25579 31334859

27. Shin H-J Kim K Lee JJ Song MK Lee EY Park SH The t (11; 14)(q13; q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma Clin Lymphoma Myeloma Leuk 2015 15 227 35 10.1016/j.clml.2014.12.007 25812994

28. Gagelmann N Eikema DJ Koster L Caillot D Pioltelli P Lleonart JB Tandem autologous stem cell transplantation improves outcomes in newly diagnosed multiple myeloma with extramedullary disease and high-risk cytogenetics: a study from the Chronic Malignancies Working Party of the European Society for blood and marrow transplantation Biol Blood Marrow Transplant 2019 25 2134 42 10.1016/j.bbmt.2019.07.004 31288095

29. Caers J Paiva B Zamagni E Leleu X Bladé J Kristinsson SY Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel J Hematol Oncol 2018 11 10. 10.1186/s13045-017-0549-1 29338789 PMC5771205

30. Varga C Xie W Laubach J Ghobrial IM O'Donnell EK Weinstock M Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations Br J Haematol 2015 169 843 50 10.1111/bjh.13382 26032514

31. Kumar L Gogi R Patel AK Mookerjee A Sahoo RK Malik PS Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome Bone Marrow Transplant 2017 52 1473 5 10.1038/bmt.2017.165 28805789

32. Lakshman A Singh PP Rajkumar SV Dispenzieri A Lacy MQ Gertz MA Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma Am J Hematol 2018 93 179 86 10.1002/ajh.24954 29067723

33. Rasche L Strifler S Duell J Rosenwald A Buck A Maeder U The lymphoma-like polychemotherapy regimen “Dexa-BEAM” in advanced and extramedullary multiple myeloma Annals Hematol 2014 93 1207 14 10.1007/s00277-014-2023-2 24526137

34. Zhou X Flüchter P Nickel K Meckel K Messerschmidt J Böckle D Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease Cancers 2020 12 1035. 10.3390/cancers12041035 32340174 PMC7225914

35. Gozzetti A Cerase A Lotti F Rossi D Palumbo A Petrucci MT Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients Cancer 2012 118 1574 84 10.1002/cncr.26447 21932386

36. Touzeau C Moreau P How I treat extramedullary myeloma Blood 2016 127 971 6 10.1182/blood-2015-07-635383 26679866

37. Egan PA Elder PT Deighan WI O’Connor SJM Alexander HD Multiple myeloma with central nervous system relapse Haematologica 2020 105 1780 90 10.3324/haematol.2020.248518 32414852 PMC7327654

38. Usmani SZ Weiss BM Plesner T Bahlis NJ Belch A Lonial S Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma Blood 2016 128 37 44 10.1182/blood-2016-03-705210 27216216 PMC4937359

39. Rapoport AP Stadtmauer EA Binder-Scholl GK Goloubeva O Vogl DT Lacey SF NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma Nat Med 2015 21 914 21 10.1038/nm.3910 26193344 PMC4529359

40. Gagelmann N Ayuk F Atanackovic D Kröger N B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis Eur J Haematol 2020 104 318 27 10.1111/ejh.13380 31883150

41. Cavo M, Goldschmidt H, Rosinol L, Pantani L, Zweegman S, Salwender HJ, et al. Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-years) analysis of randomized phase 3 studies. Am Soc Hematology 2018.

42. Cavo M, Salwender H, Rosiñol L, Moreau P, Petrucci MT, Blau IW, et al. Double vs single autologous stem cell transplantation after bortezomib-based induction regimens for multiple myeloma: an integrated analysis of patient-level data from phase European III studies. American Society of Hematology Washington, DC; 2013.

43. Pérez-Simón JA Sureda A Fernández-Aviles F Sampol A Cabrera JR Caballero D Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients Leukemia 2006 20 542 5 10.1038/sj.leu.2404085 16408097

44. Yin X Tang L Fan F Jiang Q Sun C Hu Y Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017 Cancer Cell Int 2018 18 62 10.1186/s12935-018-0553-8 29713245 PMC5913895

45. Rasche L Röllig C Stuhler G Danhof S Mielke S Grigoleit GU Allogeneic hematopoietic cell transplantation in multiple myeloma: focus on longitudinal assessment of donor chimerism, extramedullary disease, and high-risk cytogenetic features Biol Blood Marrow Transplant 2016 22 1988 96 10.1016/j.bbmt.2016.08.024 27590108

46. Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosinol L, Ozet G, et al. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. Haematologica 2019;105:201–8. 10.3324/haematol.2019.219295 PMC6939516 31278209

47. Burkat CN Van Buren JJ Lucarelli MJ Characteristics of orbital multiple myeloma: a case report and literature review Surv Ophthalmol 2009 54 697 704 10.1016/j.survophthal.2009.04.012 19709708

48. Tahiliani N Kataria P Patel A Kendre P Proptosis and hemiplegia as an initial manifestation of multiple myeloma J Postgrad Med 2018 64 243 6 10.4103/jpgm.JPGM_623_17 30117481 PMC6198690

49. Norlia, A. Recurrent multiple myeloma presenting as a breast plasmacytoma. Med J Malaysia. 2010;65:227–8. 21939175

50. Khan AM Azar I Najjar S Bevington T Mehdi S A case of aggressive multiple myeloma with extramedullary involvement of the female reproductive system, thyroid and breasts Case Rep Hematol 2019 2019 7348504. 31467739 10.1155/2019/7348504 PMC6701299

51. Singh K Kumar P Pruthy R Goyal G Multiple myeloma presenting as thyroid plasmacytoma Indian J Med Paediatr Oncol 2017 38 552 4 10.4103/ijmpo.ijmpo_43_16 29333030 PMC5759082

52. You WS Bhuta S Myeloma of laryngeal cartilage: literature review and case study Ear Nose Throat J 2019 100 145561319861379 NP119 10.1177/0145561319861379 31284752

53. Cantone E Di Lullo AM Marano L Guadagno E Mansueto G Capriglione P Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series J Med Case Rep 2017 11 219. 10.1186/s13256-017-1382-4 28793931 PMC5550939

54. D'Aguillo C, Soni RS, Gordhan C, Liu JK, Baredes S, Eloy JA, editors. Sinonasal extramedullary plasmacytoma: a systematic review of 175 patients. in International forum of allergy & rhinology. 2014. Wiley Online Library. 10.1002/alr.21254 24339430

55. Yanamandra U Deo P Sahu KK Nampoothiri RV Gupta N Prabhakaran A Clinicopathological profile of myelomatous pleural effusion: single-center real-world experience and review of literature Clin Lymphoma Myeloma Leuk 2019 19 183 9 10.1016/j.clml.2018.12.003 30704934

56. Oshima K Kanda Y Nannya Y Kaneko M Hamaki T Suguro M Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma Am J Hematol 2001 67 1 5 10.1002/ajh.1067 11279649

57. Abelman W Virchis A Yong K Extramedullary myeloma representing as a pericardial effusion with tamponade: two case reports and a further review of 19 cases in the literature Leukemia Lymphoma 2005 46 137 42 10.1080/10428190400011583 15621792

58. Wang X Xie H Zhang L Multiple myeloma with onset of pancreas involvement: a case report Medicine 2019 98 e16567 10.1097/MD.0000000000016567 31348284 PMC6708728

59. Chim CS Wong WM Nicholls J Chung LP Liang R Extramedullary sites of involvement in hematologic malignancies: case 3. Hemorrhagic gastric plasmacytoma as the primary presentation in multiple myeloma J Clin Oncol 2002 20 344 7 10.1200/JCO.2002.20.1.344 11773190

60. Karp S Shareef D Ascites as a presenting feature of multiple myeloma J R Soc Med 1987 80 182 4 10.1177/014107688708000318 3572948 PMC1290728

61. Yamashita K Horiuchi T Hayashida A Tachibana H Toki D Kondo T Multiple myeloma with testicular involvement: a case report Urol Case Rep 2019 26 100971. 10.1016/j.eucr.2019.100971 31372345 PMC6659131

62. Jurczyszyn A Olszewska-Szopa M Hungria V Crusoe E Pika T Delforge M Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients Leuk Lymphoma 2016 57 2071 6 10.3109/10428194.2015.1128542 26726867

63. Evans LA, Jevremovic D, Nandakumar B, Dispenzieri A, Buadi FK, Dingli D, et al. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. Am J Hematol. n/a (n/a). 10.1002/ajh.25773 PMC7217733 32129510